⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 25, 2011Journal of Clinical Oncology

Regulation, Role, and Targeting of Akt in Cancer

Michael A. Davies

View at Publisher

Ask AI

Bookmark

Share

Abstract

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2011.37.4751 Journal of Clinical Oncology - published online before print October 24, 2011 PMID: 22025159 Regulation, Role, and Targeting of Akt in Cancer Michael A. DaviesxMichael A. DaviesSearch for articles by this author Show More The University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.2011.37.4751 First Page Full Text PDF Figures and Tables © 2011 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Michael A. Davies (2011) studied this question.

synapsesocial.com/papers/6aab393bf104e82140f8dfcd https://doi.org/10.1200/jco.2011.37.4751

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
2Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
3KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
4Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
5Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisJournal of Clinical Oncology · 2026
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from The University of Texas MD Anderson Cancer Center